|
Office of AIDS Research Advisory Council (OARAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
OD/DPCPSI/OAR, NICHD
|
The Office of AIDS Research Advisory Council provides advice to the Director of the Office of AIDS Research (OAR) on the planning, coordination, and evaluation of research and other activities in respect to AIDS conducted or supported by the NIH. OARAC also advises the Secretary of Health and Human Services and the Director of NIH, on AIDS research programs, the development and annual review of the comprehensive plan for the conduct and support of all HIV/AIDS activities of the agencies of NIH, including research policies and priorities, and the coordination of domestic and international NIH AIDS efforts.
|
|
Office of Science and Technology Mo99 Stakeholders Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA, OSG
|
NIBIB, NCI
|
Coordinate the efforts of multiple stakeholders (Department of State, Department of Energy, Department of Homeland Security, Department of Health and Human Services, private sector) to establish a stable, long-term domestic supply of Mo99 (molybdenum-99) for medical purposes. Such a supply needs to be consistent with current international goals (to which the US is an active participant) of reduction in the use of high-enriched uranium in all reactors, including Mo99 production facilities, as well as full cost recovery solutions.
|
|
Oligonucleotide and sequencing services from FDA
|
Research Initiative
|
FDA
|
NICHD
|
This inter-agency agreement (IAA) is for the purpose of meeting the needs of a Eunice Kennedy Shriver National Institute of Child Health and Human development (NICHD) intramural lab that requires oligonucleotide and sequencing services from the Facility for Biotechnology Resources, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA). The NICHD, NIH agrees to pay the FDA for these services.
|
|
Oral Health, Cancer Care, and You
|
Public Education Campaign
|
CDC
|
NIDCR, NCI, NINR
|
A series of publications to inform health care providers and patients about steps they can take before, during, and after cancer treatment to reduce the risk and impact of the often painful side effects.
|
|
Osteoporosis and Related Bone Diseases—National Resource Center
|
Resource Development
|
OS
|
NIAMS, NIA, NICHD, NIDCR, NIDDK, OD/DPCPSI/ORWH
|
Provides patients, health professionals and the public with an important link to resources and information on metabolic bone diseases, including osteoporosis, Paget’s disease of the bone and osteogenesis imperfecta.
|
|
P63, P13K and RAS oncogenes in tumorigenesis, immune deregulation and therapy of squamous cell carcinoma
|
Research Initiative
|
FDA
|
NIDCD
|
At the FDA, Dr. Weinberg is transducing murine keratinocytes with combinations of oncogenes found in human squamous cell carcinomas to determine if they generate transformation and tumors in laboratory environment conditions. Dr. Van Waes’ laboratory at NIDCD will study how these oncogene driven tumors in mice deregulate keratinocytes and host immune responses, as well as response to various standard, molecular and immune therapies.
|
|
Panel workgroup for updating US Pediatric HIV treatment guidelines
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA
|
NICHD, NIAID
|
NICHD is the lead for updating the US Pediatric HIV treatment guidelines and serves as executive secretary.
The Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children (the Panel), a working group of the Office of AIDS Research Advisory Council (OARAC), reviews new data on an ongoing basis and provides regular updates to the guidelines. The guidelines are available on the AIDSinfo website at http://aidsinfo.nih.gov.
These updated guidelines address the use of combination antiretroviral therapy (cART) for HIV-infected infants, children, and adolescents. Guidance on management of adverse events associated with use of antiretroviral (ARV) drugs in children and a detailed review of information about safety, efficacy, and pharmacokinetics (PK) of ARV agents in children is also included.
|
|
Partners in Information Access for the Public Health Workforce
|
Resource Development
|
AHRQ, CDC, HRSA, OS
|
NLM
|
Partners in Information Access for the Public Health Workforce is a collaboration of U.S. government agencies, public health organizations, and health sciences libraries which provides timely, convenient access to selected public health resources on the Internet.
|
|
Partnership for Tuberculosis (TB) and TB/HIV Research
|
Research Initiative
|
CDC
|
NIAID
|
NIH/CDC partnership to develop methods and strategies to improve upon drug susceptibility testing methods for Pyrazinamide (PZA) and discovery of transcriptional markers of viable Mycobacterium tuberculosis (MTB) during treatment, markers of persistence, and markers of treatment response in active pulmonary Tuberculosis (TB).
|
|
Partnership for Tuberculosis (TB) and TB/HIV Research -2
|
Resource Development
|
CDC
|
NIAID
|
Support for whole genome sequencing (WGS) of isolates and bioinformatics/analytic support for WGS to characterize TB drug resistance mutations. This is a joint CDC/NIAID effort to develop a comprehensive database of resistance polymorphisms and phenotypic correlations from clinical samples from various sites worldwide.
|